Molecular imaging with copper-64 in the drug discovery and development area

Suzanne V. Smith

Research output: Contribution to journalReview articlepeer-review

17 Citations (Scopus)

Abstract

The contribution of positron emission tomography (PET) to the drug discovery and development (D3) pipeline has been inhibited by the short half-lifes of PET radioisotopes, 11C and 18F, poor availability and the high cost of infrastructure. Copper-64 (64CU) has a 12.7 h half-life, simple yet flexible radio-chemistry and imaging characteristics that make it ideal for a wider application across the D3 arena. Recent scientific breakthroughs in the production of 64Cu show that it's, commercial production can be made more widely available. More importantly, for pharmaceutical research and development programmes wishing to incorporate the high sensitivity and spatial resolution of PET, but no desire to implement and maintain expensive radiochemistry infrastructure, 64Cu is an exciting option.

Original languageEnglish
Pages (from-to)659-672
Number of pages14
JournalExpert Opinion on Drug Discovery
Volume2
Issue number5
DOIs
Publication statusPublished or Issued - May 2007
Externally publishedYes

Keywords

  • Cu
  • Clinical trials
  • Drug development
  • Drug discovery
  • PET imaging

ASJC Scopus subject areas

  • Drug Discovery

Cite this